Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP11B2 | P19099 | 11/20 | 0.51 |
| ▸ | CYP11B1 | P15538 | 8/20 | 0.51 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.51 |
| ▸ | CYP17A1 | P05093 | 1/20 | 0.51 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.51 |
| ▸ | BRD4 | O60885 | 1/20 | 0.46 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.46 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.46 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.46 |
| ▸ | TRIM24 | O15164 | 4/20 | 0.45 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.41 |
| ▸ | ATAD2 | Q6PL18 | 1/20 | 0.41 |
| ▸ | SYK | P43405 | 1/20 | 0.40 |
| ▸ | TYRO3 | Q06418 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3594131 | 0.86 | TRIM24 (0.45) | CYP11B2CYP11B1CYP1A2CYP17A1CYP19A1 | |
| SCHEMBL8556144 | 0.82 | CYP11B2 (0.51) | CYP11B2CYP11B1CYP1A2CYP17A1CYP19A1 | |
| SCHEMBL422074 | 0.80 | SRD5A1 (0.58) | CYP11B2CYP11B1CYP1A2CYP17A1CYP19A1 | |
| SCHEMBL6073575 | 0.79 | CYP11B2 (0.51) | CYP11B2CYP11B1CYP1A2CYP17A1CYP19A1 | |
| SCHEMBL736131 | 0.79 | ATAD2 (0.64) | CYP11B2CYP11B1CYP1A2CYP17A1CYP19A1 | |
| SCHEMBL11255201 | 0.79 | SRD5A1 (0.59) | CYP11B2CYP11B1CYP1A2CYP17A1CYP19A1 | |
| SCHEMBL5543650 | 0.79 | CYP11B2 (0.51) | CYP11B2CYP11B1CYP1A2CYP17A1CYP19A1 | |
| SCHEMBL265640 | 0.79 | SRD5A1 (0.59) | CYP11B2CYP11B1CYP1A2CYP17A1CYP19A1 | |
| SCHEMBL8554279 | 0.79 | CYP11B2 (0.51) | CYP11B2CYP11B1CYP1A2CYP17A1CYP19A1 | |
| SCHEMBL7380548 | 0.77 | TRIM24 (0.53) | CYP11B2CYP11B1CYP1A2CYP17A1CYP19A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100016285-A1 | HETEROCYCLIDENE-N-(ARYL) ACETAMIDE DERIVATIVE | MOCHIDA PHARMACEUTICAL CO., LTD. (JP) | 2010-01-21 | — | — | US | disclosed |
| EP-2128157-A1 | HETEROCYCLIDENE-N-(ARYL)ACETAMIDE DERIVATIVE | MOCHIDA PHARMACEUTICAL CO., LTD. (JP) | 2009-12-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100016285-A1 | HETEROCYCLIDENE-N-(ARYL) ACETAMIDE DERIVATIVE | CCNY, CCND3, NSD3 | CYP11B2 165/4885CYP11B1 162/4885CYP1A2 145/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.